325 related articles for article (PubMed ID: 27304831)
21. Metformin for weight control in pediatric patients on atypical antipsychotic medication.
Shin L; Bregman H; Breeze JL; Noyes N; Frazier JA
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):275-9. PubMed ID: 19519262
[TBL] [Abstract][Full Text] [Related]
22. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
Miller LJ
Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
Ellinger LK; Ipema HJ; Stachnik JM
Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
[TBL] [Abstract][Full Text] [Related]
24. Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX).
Siskind D; Russell A; Gamble C; Baker A; Cosgrove P; Burton L; Kisely S
J Psychiatr Res; 2020 May; 124():9-12. PubMed ID: 32087425
[TBL] [Abstract][Full Text] [Related]
25. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
Khan AY; Macaluso M; McHale RJ; Dahmen MM; Girrens K; Ali F
J Psychiatr Pract; 2010 Sep; 16(5):289-96. PubMed ID: 20859106
[TBL] [Abstract][Full Text] [Related]
26. Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Chiu CC; Lu ML; Huang MC; Chen PY; Lin YK; Lin SK; Chen CH
PLoS One; 2016; 11(12):e0168347. PubMed ID: 27973619
[TBL] [Abstract][Full Text] [Related]
27. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
[TBL] [Abstract][Full Text] [Related]
28. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).
Siskind DJ; Russell AW; Gamble C; Winckel K; Mayfield K; Hollingworth S; Hickman I; Siskind V; Kisely S
Diabetes Obes Metab; 2018 Apr; 20(4):1050-1055. PubMed ID: 29194917
[TBL] [Abstract][Full Text] [Related]
29. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T; McCutcheon RA; Vano L; Mizuno Y; Arumuham A; Hindley G; Beck K; Natesan S; Efthimiou O; Cipriani A; Howes OD
Lancet Psychiatry; 2020 Jan; 7(1):64-77. PubMed ID: 31860457
[TBL] [Abstract][Full Text] [Related]
30. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
[TBL] [Abstract][Full Text] [Related]
31. Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis.
Ellul P; Delorme R; Cortese S
CNS Drugs; 2018 Dec; 32(12):1103-1112. PubMed ID: 30238318
[TBL] [Abstract][Full Text] [Related]
32. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.
Bai YM; Chen JY; Yang WS; Chi YC; Liou YJ; Lin CC; Wang YC; Lin CY; Su TP; Chou P
J Clin Psychiatry; 2007 Dec; 68(12):1834-9. PubMed ID: 18162013
[TBL] [Abstract][Full Text] [Related]
33. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
[TBL] [Abstract][Full Text] [Related]
34. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
de Silva VA; Suraweera C; Ratnatunga SS; Dayabandara M; Wanniarachchi N; Hanwella R
BMC Psychiatry; 2016 Oct; 16(1):341. PubMed ID: 27716110
[TBL] [Abstract][Full Text] [Related]
35. A systematic review of metformin to limit weight-gain with atypical antipsychotics.
Lee YJ; Jeong JH
J Clin Pharm Ther; 2011 Oct; 36(5):537-45. PubMed ID: 21418264
[TBL] [Abstract][Full Text] [Related]
36. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
Siskind D; McCartney L; Goldschlager R; Kisely S
Br J Psychiatry; 2016 Nov; 209(5):385-392. PubMed ID: 27388573
[TBL] [Abstract][Full Text] [Related]
37. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Wu RR; Zhang FY; Gao KM; Ou JJ; Shao P; Jin H; Guo WB; Chan PK; Zhao JP
Mol Psychiatry; 2016 Nov; 21(11):1537-1544. PubMed ID: 26809842
[TBL] [Abstract][Full Text] [Related]
38. Treatment of clozapine-associated weight gain: a systematic review.
Whitney Z; Procyshyn RM; Fredrikson DH; Barr AM
Eur J Clin Pharmacol; 2015 Apr; 71(4):389-401. PubMed ID: 25627831
[TBL] [Abstract][Full Text] [Related]
39. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Ghanizadeh A; Nikseresht MS; Sahraian A
Schizophr Res; 2013 Jun; 147(1):110-115. PubMed ID: 23583010
[TBL] [Abstract][Full Text] [Related]
40. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ
Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
